Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
HAE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$58.80 - $97.97
Previous CloseN/A
Volume53.78K
Average Volume (3M)912.04K
Market Cap
$3.23B
Enterprise Value$4.83B
Total Cash (Recent Filing)$320.85M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)25.3
Beta0.98
Next Earnings
May 13, 2025EPS Estimate
1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.54
Shares Outstanding50,237,465
10 Day Avg. Volume727,296
30 Day Avg. Volume912,040
Financial Highlights & Ratios
PEG Ratio9.92
Price to Book (P/B)N/A
Price to Sales (P/S)2.34
Price to Cash Flow (P/CF)18.40
P/FCF Ratio22.80
Enterprise Value/Market Cap1.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.99
Enterprise Value/Ebitda18.37
Forecast
1Y Price Target
$96.71Price Target Upside50.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
---
Haemonetics News
PremiumCompany Announcements
Haemonetics Announces Key Executive Leadership Changes
PremiumCompany Announcements
Haemonetics Earnings Call: Growth Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Management StrategyManagement is committed to achieving a premium MedTech profile, targeting high-single digit organic sales growth, ~60%+ gross margin and high-20%’s operating margin sustainably.
Market ShareThe outlook looks bright as the company captures material share, benefits from continued pricing gains, and collections improve.
PartnershipsThe announcement of new long-term contracts with two key Plasma customers helps dispel the long-standing fears of competition.
Bears Say
Financial PerformanceThe sale of whole blood assets led to a decrease in projected revenue and earnings per share for upcoming years.
Product Roll-OutThe roll-out of VASCADE MVP XL was slower than expected and compounded by VASCADE slippage across coronary and peripheral procedures likely to persist near-term.
Stock PerformanceThe stock has seen a steady decline due to concerns like slowing base plasma collections and the rate of VASCADE XL uptake.
---
Ownership Overview
1.18% Insiders
49.55% Mutual Funds
0.21% Other Institutional Investors
23.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HAE FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was $58.80 and its highest was $97.97 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Haemonetics Corp.’s market cap is $3.23B.
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is May 13, 2025 which is in 46 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Feb 06, 2025. The company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.174 by $0.016.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is 1.22.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 50,237,465 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of $1.19 in its last earnings report, beating expectations of $1.174. Following the earnings report the stock price went down -11.581%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Currently, no hedge funds are holding shares in HAE
---
Haemonetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$96.71 (50.62% Upside)
$96.71 (50.62% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 85%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 41.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.64%
12-Months-Change
Fundamentals
Return on Equity
14.06%
Trailing 12-Months
Asset Growth
15.04%
Trailing 12-Months
Company Description
Haemonetics Corp.
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
---
HAE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong growth in the hospital and interventional technologies segments offset by declines in plasma revenue and challenges in China. The company's ability to secure new long-term agreements and record operating margins are positive signs, but the issues with cash flow and certain product lines indicate areas needing improvement.Read More>---
HAE Stock 12 Month Forecast
Average Price Target
$96.71
▲(50.62% Upside)
Technical Analysis
Baxter International
―
Boston Scientific
―
Edwards Lifesciences
―
Hologic
―
Zimmer Biomet Holdings
―
Best Analysts Covering HAE
1 Year
1 Year Success Rate
28/49 ratings generated profit
1 Year Average Return
+6.24%
reiterated a buy rating 2 months ago
Copying Anthony Petrone's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +6.24% per trade.
---